Travere Therapeutics (TVTX) Other Non Operating Income (2013 - 2026)

Travere Therapeutics has reported Other Non Operating Income for 14 years, with the latest figure at -$91000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income fell 116.58% year-over-year to -$91000.0; the trailing twelve-month figure through Mar 2026 stood at $10.9 million (up 463.72% YoY), and the FY2025 full-year result was $11.6 million, up 448.95% from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$91000.0, down from $11.1 million in the prior quarter.
• The five-year high for Other Non Operating Income was $11.1 million in Q4 2025, with the low at -$3.5 million in Q2 2024.
• Historically, Other Non Operating Income has averaged $573812.5 across 5 years, with a median of $56500.0 in 2022.
• Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 6345.45% — and 2024, when it plunged 1638.81%.
• Travere Therapeutics' Other Non Operating Income stood at -$22000.0 in 2022, then jumped by 6345.45% to $1.4 million in 2023, then slumped by 142.29% to -$581000.0 in 2024, then jumped by 2004.82% to $11.1 million in 2025, then sank by 100.82% to -$91000.0 in 2026.
• The last three Other Non Operating Income figures came in at -$91000.0 (Q1 2026), $11.1 million (Q4 2025), and $487000.0 (Q3 2025), per Business Quant data.